B-raf gene is a kind of oncogene and the coded protein is an important regulatory factor in RAS-RAF-MEK-ERK signaling pathway. When this pathway is abnormally activated, it can promote cell proliferation and growth, and eventually leads to tumorigenesis. Studies have shown that there are different frequencies of B-raf oncogene mutations in a variety of human tumors, such as malignant melanoma, papillary thyroid cancer and colorectal cancer.
The shelf life of kit is 12 months when stored in a freezer at -(20±5) ℃.
1. Coincidence rate of enterprise references: Coincidence rate of 12 negative references is 12/12, of 8 positive references is 8/8.
2. LoD: when detect a 1.0 % ratio of mutated DNA in a total 50 ng/μL genomic DNA, the result should be V600E positive.
3. Precision: the coefficient of variation of inter- and intra- batches are both not higher than 15%.
Medication Guide 1:
Patients with wild-type K-ras gene and mutations in B-raf gene show ineffective treatment with EGFR inhibitors such as cetuximab and panitumumab
Medication Guide 2:
Panitumumab and Erbitux have significant curative effect in patients with wild-type tumors of B-raf gene
Prognostic Indicators:
B-raf mutation is not only a predictive indicator, but also a prognostic indicator. The colorectal cancer patients with B-raf mutation has a poor prognosis.
Flyer